First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II).

BACKGROUND: Palliative systemic therapy alternated with electrostatic precipitation oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (ePIPAC) has never been prospectively investigated in patients with unresectable colorectal peritoneal metastases (CPM). The CRC-PIPAC-II study aimed to assess safety, feasibility and efficacy of such bidirectional therapy. METHODS: This two-center, single-arm, phase II trial enrolled chemotherapy-naïve patients to undergo three treatment cycles, consisting of systemic therapy (CAPOX, FOLFOX, FOLFIRI, or FOLFOXIRI, all with bevacizumab) and oxaliplatin-based ePIPAC (92 mg/m2) with intravenous leucovorin (20 mg/m2) and 5-fluorouracil (400 mg/m2). Primary outcome were major treatment-related adverse events. Secondary outcomes included minor events, tumor response, progression-free survival (PFS) and overall survival (OS). RESULTS: Twenty patients completed 52 treatment cycles. Fifteen major events occurred in 7 patients (35 %): 5 events (33 %) related to systemic therapy; 5 (33 %) related to ePIPAC; and 5 (33 %) were biochemical events. No treatment-related deaths occurred. All patients experienced minor events, mostly abdominal pain, nausea and peripheral sensory neuropathy. After treatment, radiological, pathological, cytological, and biochemical response was observed in 0 %, 88 %, 38 %, and 31 % of patients respectively. Curative surgery was achieved in one patient. Median PFS was 10.0 months (95 % confidence interval [CI] 8.0-13.0) and median OS was 17.5 months (95 % CI 13.0-not reached). CONCLUSIONS: Combining palliative systemic therapy with oxaliplatin-based ePIPAC in patients with unresectable CPM was feasible and showed an acceptable safety profile. Treatment-induced response and survival are promising, yet further research is required to determine the additional value of ePIPAC to systemic therapy.

Glutathione-Coated Gold Nanoparticles Enabling Bifunctional Therapy at the Buried Interface for Efficient and UV-Resistant Perovskite Solar Cells.

Very recently, the poor contact between the perovskite and carrier selective layer has been regarded as a critical issue for improving the performance and stability of perovskite solar cells (PSCs). In this study, the buried interface of regularly structured PSCs has been targeted. Glutathione-coated gold nanoparticles (GSH-AuNPs) are used as double-sided passivating agents to improve the quality of the perovskite films. It has been demonstrated that the GSH-AuNPs interact strongly with the SnO2 underlayer and the upper perovskite layer, significantly reducing the defect densities of this interface. Thus, the power conversion efficiency (PCE) of the PSCs can be increased from 20.46% (control, 19.38%, IPCE corrected) to 22.22% (GSH-AuNPs modified, 21.10%, IPCE corrected) with notable enhancement in Voc and FF. Moreover, the strong interaction between the C═O groups of GSH-AuNPs and the undercoordinated Pb2+ species of the perovskite films inhibits the formation of metallic Pb0. As a result, the unencapsulated GSH-AuNPs-modified devices retained 80% of their initial PCEs after 1000 h at ambient conditions, with a relative humidity (RH) of 60 ± 5%. UV-resistant PSCs have also been demonstrated after introducing GSH-AuNPs. Therefore, our findings demonstrate the bidirectional therapy strategy as a feasible approach for achieving efficient and UV-resistant PSCs.